Somatorelin - ICN

Drug Profile

Somatorelin - ICN

Alternative Names: GRF 1-44; Growth hormone releasing factor (1-44); Somatoliberin

Latest Information Update: 03 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fujisawa
  • Developer Roche; Valeant Pharmaceuticals International
  • Class Amino acids; Hormones; Peptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Muscular atrophy; Somatotropin deficiency

Most Recent Events

  • 15 Feb 1999 Phase-I clinical trials for Muscle wasting in Switzerland (Implant)
  • 13 Nov 1997 Phase-II clinical trials for Muscle wasting in Yugoslavia (Parenteral)
  • 09 Jul 1997 Phase-III clinical trials for Somatotropin deficiency in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top